Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
2005 1
2006 1
2010 1
2016 3
2017 1
2019 1
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
The role of PET in lymphoma.
Jhanwar YS, Straus DJ. Jhanwar YS, et al. J Nucl Med. 2006 Aug;47(8):1326-34. J Nucl Med. 2006. PMID: 16883013 Free article. Review.
Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis.
Braunstein MJ, Petrova-Drus K, Rosenbaum CA, Jayabalan DS, Rossi AC, Salvatore S, Rech K, Pearse RN, Hassane DC, Postley J, Jhanwar YS, Geyer JT, Niesvizky R. Braunstein MJ, et al. Among authors: jhanwar ys. Am J Clin Pathol. 2020 Nov 4;154(6):767-775. doi: 10.1093/ajcp/aqaa095. Am J Clin Pathol. 2020. PMID: 32705137
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
Niaz MJ, Batra JS, Walsh RD, Ramirez-Fort MK, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne JR, Bander NH, Tagawa ST. Niaz MJ, et al. Among authors: jhanwar ys. Oncologist. 2020 Jun;25(6):477-e895. doi: 10.1634/theoncologist.2020-0028. Epub 2020 Jan 30. Oncologist. 2020. PMID: 31999003 Free PMC article.
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ, Bander NH, Nanus DM. Tagawa ST, et al. Among authors: jhanwar ys. Cancer. 2019 Aug 1;125(15):2561-2569. doi: 10.1002/cncr.32072. Epub 2019 Apr 23. Cancer. 2019. PMID: 31012963 Free article. Clinical Trial.
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.
Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne JR, Bander NH, Tagawa ST. Batra JS, et al. Among authors: jhanwar ys. Urol Oncol. 2020 Nov;38(11):848.e9-848.e16. doi: 10.1016/j.urolonc.2020.05.028. Epub 2020 Jun 27. Urol Oncol. 2020. PMID: 32600929 Clinical Trial.
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.
Beattie BJ, Smith-Jones PM, Jhanwar YS, Schöder H, Schmidtlein CR, Morris MJ, Zanzonico P, Squire O, Meirelles GS, Finn R, Namavari M, Cai S, Scher HI, Larson SM, Humm JL. Beattie BJ, et al. Among authors: jhanwar ys. J Nucl Med. 2010 Feb;51(2):183-92. doi: 10.2967/jnumed.109.066159. Epub 2010 Jan 15. J Nucl Med. 2010. PMID: 20080885 Free PMC article.
12 results